{"id":"lamotrigine-tablets","safety":{"commonSideEffects":[{"rate":"10%","effect":"Headache"},{"rate":"8%","effect":"Dizziness"},{"rate":"6%","effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL741","moleculeType":"Small molecule","molecularWeight":"256.10"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Lamotrigine is a phenyltriazine anticonvulsant that stabilizes neuronal membranes by inhibiting the release of excitatory neurotransmitters such as glutamate and aspartate.","oneSentence":"Blocks voltage-sensitive sodium channels","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T04:03:04.614Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Epilepsy"}]},"trialDetails":[{"nctId":"NCT06184581","phase":"PHASE4","title":"Lithium Versus Lamotrigine in Bipolar Disorder, Type II","status":"RECRUITING","sponsor":"University Hospital Bispebjerg and Frederiksberg","startDate":"2024-05-08","conditions":"Bipolar II Disorder","enrollment":200},{"nctId":"NCT03689114","phase":"PHASE4","title":"Low vs. Standard Daily Doses of Antiepileptic Drugs in Newly Diagnosed, Previously Untreated Epilepsy(STANDLOW)","status":"COMPLETED","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2021-05-10","conditions":"Epilepsies, Partial","enrollment":58},{"nctId":"NCT00838279","phase":"PHASE1","title":"Lamotrigine 25 mg Chewable Tablets, Fasting","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","startDate":"2002-02","conditions":"Healthy","enrollment":32},{"nctId":"NCT00838136","phase":"PHASE1","title":"Lamotrigine 25 mg Chewable Tablets, Non-Fasting","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","startDate":"2002-02","conditions":"Healthy","enrollment":32},{"nctId":"NCT00835263","phase":"PHASE1","title":"Bioequivalence Study of 200 mg Lamotrigine Tablet Under Non-Fasting Conditions","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","startDate":"2002-01","conditions":"Healthy","enrollment":32},{"nctId":"NCT00834561","phase":"PHASE1","title":"Bioequivalence Study of 200 mg Lamotrigine Tablet Under Fasting Conditions","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","startDate":"2002-01","conditions":"Healthy","enrollment":32},{"nctId":"NCT05881928","phase":"PHASE4","title":"Effect of Adding Lamotrigine to Sodium Valproate in Childhood Epilepsy: Clinicolabratory Study","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2024-07-29","conditions":"Epilepsy, Lamotrigine, Sodium Valproate Adverse Reaction","enrollment":50},{"nctId":"NCT00647751","phase":"PHASE1","title":"Food Study of Lamotrigine Tablets 25 mg to Lamictal® Tablets 25 mg","status":"COMPLETED","sponsor":"Mylan Pharmaceuticals Inc","startDate":"2004-08","conditions":"Healthy","enrollment":28},{"nctId":"NCT00650208","phase":"PHASE1","title":"Fasting Study of Lamotrigine Tablets 25 mg to Lamictal® Tablets 25 mg","status":"COMPLETED","sponsor":"Mylan Pharmaceuticals Inc","startDate":"2004-07","conditions":"Healthy","enrollment":27},{"nctId":"NCT05450822","phase":"","title":"Precision Medicine in the Treatment of Epilepsy","status":"RECRUITING","sponsor":"Gitte Moos Knudsen","startDate":"2022-02-18","conditions":"Epilepsy","enrollment":550},{"nctId":"NCT04602221","phase":"PHASE1","title":"A Study in Healthy Men to Test Whether BI 409306, BI 425809 or Lamotrigine Can Reverse the Memory Problems Caused by Ketamine","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2020-12-01","conditions":"Healthy","enrollment":40},{"nctId":"NCT06199791","phase":"PHASE1","title":"Single-dose, Two-way Crossover Bioequivalence of Lamotrigine in Healthy Male Volunteers Under Fasting Conditions","status":"COMPLETED","sponsor":"Desitin Arzneimittel GmbH","startDate":"2023-04-03","conditions":"Fasting","enrollment":24},{"nctId":"NCT05748236","phase":"PHASE4","title":"The Efficacy and Safety of Lamotrigine Versus Carbamazepine in Focal Epilepsy","status":"UNKNOWN","sponsor":"Dhaka Medical College","startDate":"2022-11-01","conditions":"Focal Epilepsy","enrollment":70},{"nctId":"NCT05639257","phase":"NA","title":"Treatment of Myotonia - Lamotrigine Versus Namuscla","status":"UNKNOWN","sponsor":"Grete Andersen, MD","startDate":"2022-12-05","conditions":"Non-Dystrophic Myotonia","enrollment":32},{"nctId":"NCT05017155","phase":"PHASE3","title":"MExiletine Versus Lamotrigine in Non-Dystrophic Myotonias","status":"UNKNOWN","sponsor":"University College, London","startDate":"2021-08-12","conditions":"Non-Dystrophic Myotonia","enrollment":60},{"nctId":"NCT04938856","phase":"PHASE1","title":"Bioequivalence of Lamnet (Lamotrigine)100mg Tablet With the Reference Product Lamictal 100mg (Lamotrigine) Tablet Under Fasting Conditions","status":"COMPLETED","sponsor":"University of Karachi","startDate":"2020-09-04","conditions":"Bioequivalence","enrollment":26},{"nctId":"NCT05145608","phase":"PHASE1","title":"Comparative Bioavailability Study of Lamotrigine ER Tablets USP 50 mg","status":"COMPLETED","sponsor":"Alembic Pharmaceuticals Ltd.","startDate":"2018-01-10","conditions":"Bioequivalence","enrollment":22},{"nctId":"NCT01995825","phase":"PHASE4","title":"Lamotrigine Bioequivalence","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2012-05","conditions":"Epilepsy","enrollment":35},{"nctId":"NCT00088452","phase":"PHASE3","title":"Childhood Absence Epilepsy Rx PK-PD-Pharmacogenetics Study","status":"COMPLETED","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2004-07","conditions":"Childhood Absence Epilepsy, Petit Mal Epilepsy, Epilepsy","enrollment":453},{"nctId":"NCT03116828","phase":"PHASE4","title":"A Study of a Drug to be Used in Addition With Another Drug to Treat Adults With Uncontrolled Partial-onset Seizures","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2017-07-07","conditions":"Epilepsy With Partial On-set Seizures","enrollment":102},{"nctId":"NCT02821338","phase":"PHASE1","title":"A Bioavailability Crossover Study of Two Formulations of Lamotrigine Extended Release Tablets in Healthy Subjects","status":"COMPLETED","sponsor":"Food and Drug Administration (FDA)","startDate":"2016-06","conditions":"Healthy","enrollment":30},{"nctId":"NCT02256124","phase":"PHASE2, PHASE3","title":"Effect of Lamotrigine on Cognition in NF1","status":"TERMINATED","sponsor":"Erasmus Medical Center","startDate":"2014-10","conditions":"Neurofibromatosis Type 1","enrollment":41},{"nctId":"NCT01674010","phase":"PHASE2","title":"Safety and Efficacy Study of ELND005 as an Adjunctive Maintenance Treatment in Bipolar I Disorder","status":"TERMINATED","sponsor":"OPKO Health, Inc.","startDate":"2012-08","conditions":"Bipolar 1 Disorder","enrollment":309},{"nctId":"NCT04015687","phase":"PHASE1","title":"A Study to Evaluate the Effect of AG-881 on the Pharmacokinetics of a Single Dose of Lamotrigine in Healthy Adults","status":"COMPLETED","sponsor":"Agios Pharmaceuticals, Inc.","startDate":"2019-07-15","conditions":"Healthy Participants","enrollment":22},{"nctId":"NCT02404168","phase":"PHASE4","title":"BEEP Follow Up: Evaluation of Repeatability of Lamotrigine Pharmacokinetics in Epileptic Patients","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2015-07-07","conditions":"Epilepsy","enrollment":4},{"nctId":"NCT00419003","phase":"PHASE4","title":"Research Study for Major Depressive Disorder: Investigation of Glutamate Medications","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2006-12","conditions":"Major Depression","enrollment":26},{"nctId":"NCT03898011","phase":"PHASE1","title":"A Bioequivalence Study of Two Formulations Lamotrigine 100 mg Tablets and Lamictal 100 mg Tablets in Healthy Adult Volunteers Under Fasting Conditions","status":"COMPLETED","sponsor":"Pharmtechnology LLC","startDate":"2019-03-23","conditions":"Healthy Adults","enrollment":28},{"nctId":"NCT02989727","phase":"PHASE4","title":"Melancholic Symptoms in Bipolar Depression and Responsiveness to Lamotrigine","status":"COMPLETED","sponsor":"University of Saskatchewan","startDate":"2003-11","conditions":"Depression, Bipolar Disorder, Bipolar Depression","enrollment":150},{"nctId":"NCT00243152","phase":"NA","title":"Evaluation of Lamotrigine on Neuropathic Facial Pain Using fMRI","status":"COMPLETED","sponsor":"Pain and Analgesia Imaging and Neuroscience Group","startDate":"2005-10","conditions":"Facial Neuropathy","enrollment":6},{"nctId":"NCT00916149","phase":"NA","title":"Cognitive Effects of Treatment of Interictal Discharges","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2007-01","conditions":"Epilepsy","enrollment":31},{"nctId":"NCT02413918","phase":"PHASE4","title":"Iloperidone in Mixed States of Bipolar Disorder","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2012-04","conditions":"Bipolar Disorder","enrollment":41},{"nctId":"NCT02100644","phase":"PHASE4","title":"Valproate Dose Reduction and Its Clinical Evaluation by Introducing Lamotrigine in Japanese Women With Epilepsy - Single Arm, Multicenter, and Open-label Study","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-04-12","conditions":"Epilepsy","enrollment":33},{"nctId":"NCT00939614","phase":"PHASE1","title":"Study of Lamotrigine 2×25 mg IR Tablets of Torrent Pharmaceuticals Limited, India and Lamictal® (Lamotrigine) 2×25 mg Tablets of GlaxoSmithKline, USA, in Healthy Human Adult Subjects, Under Fasting Conditions.","status":"COMPLETED","sponsor":"Torrent Pharmaceuticals Limited","startDate":"","conditions":"Healthy","enrollment":""},{"nctId":"NCT00939458","phase":"PHASE1","title":"Study of Lamotrigine 2 x 25 mg IR Tablets of Torrent Pharmaceuticals Pvt., Ltd., India and Lamictal ® (Lamotrigine) 2 x 25 mg Tablets of Glaxo-SmithKline, USA, in Healthy Human Adult Subjects, Under Fed Conditions","status":"COMPLETED","sponsor":"Torrent Pharmaceuticals Limited","startDate":"","conditions":"Healthy","enrollment":""},{"nctId":"NCT00144872","phase":"PHASE1","title":"LAMICTAL (Lamotrigine) For The Treatment Of Absence Seizures","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2004-11-01","conditions":"Seizure, Absence","enrollment":54},{"nctId":"NCT01357902","phase":"PHASE1","title":"Lamotrigine Bioequivalence Study to Compare Dispersible Tables With Compressed Tablets in China","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-04-18","conditions":"Epilepsy","enrollment":24},{"nctId":"NCT01891890","phase":"PHASE3","title":"Cognitive AED Outcomes in Pediatric Localization Related Epilepsy (COPE)","status":"TERMINATED","sponsor":"Emory University","startDate":"2013-08","conditions":"Epilepsy, Partial, Epilepsy, Localization Related","enrollment":72},{"nctId":"NCT00410371","phase":"PHASE1","title":"Study to Compare Two Formulations of Lamotrigine in Healthy Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-12-28","conditions":"Mental Disorders","enrollment":96},{"nctId":"NCT00605371","phase":"PHASE1","title":"Bioequivalence and Food Effect of 250mg of Lamotrigine XR","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-01-15","conditions":"Epilepsy","enrollment":209},{"nctId":"NCT00449774","phase":"PHASE1","title":"Bioequivalence And Effect Of Food And Water On Lamotrigine in Healthy Volunteers","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-05-07","conditions":"Mental Disorders","enrollment":220},{"nctId":"NCT00412191","phase":"PHASE1","title":"Bioequivalence And Lack Of Food Effects Of 300mg Lamotrigine XR","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-02-06","conditions":"Epilepsy","enrollment":180},{"nctId":"NCT00627575","phase":"PHASE1","title":"AED/Statin Interaction Study","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-02-04","conditions":"Epilepsy","enrollment":119},{"nctId":"NCT00907985","phase":"PHASE1","title":"A Study to Evaluate the Effect of Single Doses of Drug A (Lamotrigine) and Drug B (Vofopitant) Alone and in Combination on Resting Motor Threshold in Healthy Subjects","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2009-05-15","conditions":"Bipolar Disorder","enrollment":12},{"nctId":"NCT01879423","phase":"PHASE1","title":"The Bioequivalence Study of Lamotrigine Dispersible/Chewable Tablets 5mg×5 Compared With Lamotrigine Compressed Tablet 25mg in Chinese Healthy Male Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-04-28","conditions":"Epilepsy","enrollment":24},{"nctId":"NCT02064465","phase":"PHASE1","title":"The Bioequivalence Study of Lamotrigine Dispersible/Chewable Tablets 100mg Compared With Compressed Tablet 100 mg","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-03-15","conditions":"Epilepsy","enrollment":138},{"nctId":"NCT02513654","phase":"PHASE1","title":"Pharmacokinetics, Safety and Tolerability of Repeat Dosing Lamotrigine in Healthy Chinese Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-09-06","conditions":"Bipolar Disorder","enrollment":16},{"nctId":"NCT01602510","phase":"PHASE3","title":"Lamotrigine Phase III Study in Bipolar I Disorder","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-08","conditions":"Bipolar Disorder","enrollment":265},{"nctId":"NCT00355082","phase":"PHASE3","title":"Conversion To Monotherapy With Lamictal Extended Release Tablets For Treatment Of Partial Epilepsy","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-05","conditions":"Epilepsy, Partial","enrollment":226},{"nctId":"NCT00579982","phase":"PHASE3","title":"An Open-Label Trial Measuring Satisfaction And Convenience Of Two Formulations Of Lamotrigine In Subjects With A Mood Disorder","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-01","conditions":"Mood Disorders","enrollment":97},{"nctId":"NCT01376180","phase":"","title":"Drug Use Investigation for LAMICTAL","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-12","conditions":"Epilepsy","enrollment":3000},{"nctId":"NCT01863602","phase":"","title":"Special Drug Use Investigation for LAMICTAL® (Long Term)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-04","conditions":"Epilepsy","enrollment":850},{"nctId":"NCT01428518","phase":"","title":"Special Drug Use Investigation for LAMICTAL Bipolar","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-11","conditions":"Bipolar Disorder","enrollment":1036},{"nctId":"NCT01939561","phase":"PHASE3","title":"Lamotrigine as Treatment of Myotonia","status":"COMPLETED","sponsor":"Grete Andersen, MD","startDate":"2013-11","conditions":"Dystrophia Myotonica Type 1, Myotonia Congenita, Paramyotonia Congenita","enrollment":27},{"nctId":"NCT00272025","phase":"PHASE1","title":"Treatment Resistant Bipolar Depression","status":"TERMINATED","sponsor":"Queen's University","startDate":"2006-10","conditions":"Bipolar Depression","enrollment":1},{"nctId":"NCT00621842","phase":"PHASE3","title":"Lamotrigine for Symptoms of Geriatric Bipolar Depression","status":"COMPLETED","sponsor":"University Hospitals Cleveland Medical Center","startDate":"2008-01","conditions":"Bipolar Disorder, Depression, Bipolar","enrollment":57},{"nctId":"NCT00277212","phase":"PHASE4","title":"A Phase IV Study of the Safety and Efficacy of Aripiprazole in Combination With Lamotrigine in the Long-Term Maintenance Treatment of Patients With Bipolar I Disorder With A Recent Manic or Mixed Episode","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2005-12","conditions":"Bipolar Disorder","enrollment":1169},{"nctId":"NCT00321516","phase":"PHASE1","title":"Drug-drug Interaction Study of Aripiprazole and Lamotrigine in Patients With Bipolar Type I Disorder","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2006-07","conditions":"Bipolar Disorder","enrollment":20},{"nctId":"NCT01888757","phase":"PHASE1","title":"Lamotrigine Extended-Release Tablets 50 mg Under Fed Condition","status":"COMPLETED","sponsor":"Dr. Reddy's Laboratories Limited","startDate":"2010-09","conditions":"Healthy","enrollment":62},{"nctId":"NCT01888731","phase":"PHASE1","title":"Bioequivalence Study of Lamotrigine Extended-Release Tablets 50 mg Under Fasting Condition","status":"COMPLETED","sponsor":"Dr. Reddy's Laboratories Limited","startDate":"2010-08","conditions":"Healthy","enrollment":62},{"nctId":"NCT01888263","phase":"PHASE1","title":"Bioequivalence Study of Lamotrigine Extended-Release Tablets 200mg Under Fed Condition","status":"COMPLETED","sponsor":"Dr. Reddy's Laboratories Limited","startDate":"2010-08","conditions":"Healthy","enrollment":32},{"nctId":"NCT01888250","phase":"PHASE1","title":"Bioequivalence Study of Lamotrigine Extended-Release Tablets 200mg Under Fasting Condition","status":"COMPLETED","sponsor":"Dr. Reddy's Laboratories Limited","startDate":"2010-08","conditions":"Healthy","enrollment":36},{"nctId":"NCT00292461","phase":"PHASE3","title":"A Study for Evaluating the Efficacy and Safety of Zonisamide and Lamotrigine (Lamictal) for Subjects With Refractory Simple Partial, Complex Partial or Partial With Secondary Generalized Seizures","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2006-03","conditions":"Epilepsy","enrollment":64},{"nctId":"NCT01618825","phase":"PHASE1","title":"Bioequivalence Study of Lamotrigine Tablets 25 mg (2 x 25 mg Tablets) Under Fed Condition","status":"COMPLETED","sponsor":"IPCA Laboratories Ltd.","startDate":"2012-03","conditions":"Fed","enrollment":28},{"nctId":"NCT01618799","phase":"PHASE1","title":"Bioequivalence Study of Lamotrigine Tablets 25 mg (2 x 25 mg Tablets) Under Fasting Condition","status":"COMPLETED","sponsor":"IPCA Laboratories Ltd.","startDate":"2012-03","conditions":"Fasting State","enrollment":28},{"nctId":"NCT01513720","phase":"PHASE1","title":"Bioequivalence Study for Lamotrigine Tablets 200 mg Under Fasting Condition","status":"COMPLETED","sponsor":"Dr. Reddy's Laboratories Limited","startDate":"2002-12","conditions":"Healthy","enrollment":20},{"nctId":"NCT01513681","phase":"PHASE1","title":"Bioequivalence Study for Lamotrigine Tablets 200 mg Under Fed Condition","status":"COMPLETED","sponsor":"Dr. Reddy's Laboratories Limited","startDate":"2002-11","conditions":"Healthy","enrollment":20},{"nctId":"NCT00277641","phase":"PHASE3","title":"Lamotrigine in the Treatment of Binge Eating Disorder Associated With Obesity","status":"COMPLETED","sponsor":"Lindner Center of HOPE","startDate":"2006-03","conditions":"Binge Eating Disorder, Obesity","enrollment":70},{"nctId":"NCT01131949","phase":"PHASE1","title":"Bioequivalence Study of Lamotrigine 25 mg Chewable Tablets of Dr.Reddy's Under Fasting Condition","status":"COMPLETED","sponsor":"Dr. Reddy's Laboratories Limited","startDate":"2003-01","conditions":"Healthy","enrollment":26},{"nctId":"NCT01131975","phase":"PHASE1","title":"Bioequivalence Study of Lamotrigine 25 mg Chewable Tablets of Dr.Reddy's Under Fed Condition","status":"COMPLETED","sponsor":"Dr. Reddy's Laboratories Limited","startDate":"2003-01","conditions":"Healthy","enrollment":26},{"nctId":"NCT00901407","phase":"NA","title":"Lamotrigine Augmentation in Resistant Depression","status":"COMPLETED","sponsor":"Louisiana State University Health Sciences Center in New Orleans","startDate":"2003-12","conditions":"Unipolar Depression","enrollment":138},{"nctId":"NCT00634062","phase":"PHASE4","title":"Study of Lamotrigine Treatment of Affective Instability in Borderline Personality Disorder","status":"COMPLETED","sponsor":"Mclean Hospital","startDate":"2004-12","conditions":"Borderline Personality Disorder","enrollment":28}],"_emaApprovals":[],"_faersSignals":[{"count":97,"reaction":"DRUG INEFFECTIVE"},{"count":84,"reaction":"TOXICITY TO VARIOUS AGENTS"},{"count":64,"reaction":"PRODUCT SUBSTITUTION ISSUE"},{"count":49,"reaction":"RASH"},{"count":47,"reaction":"DIZZINESS"},{"count":46,"reaction":"NAUSEA"},{"count":45,"reaction":"DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS"},{"count":42,"reaction":"SEIZURE"},{"count":39,"reaction":"HEADACHE"},{"count":38,"reaction":"INTENTIONAL OVERDOSE"}],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Lamotrigine tablets","genericName":"Lamotrigine tablets","companyName":"GlaxoSmithKline","companyId":"glaxosmithkline","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Blocks voltage-sensitive sodium channels Used for Epilepsy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}